chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient was only 15yo and received a Moderna vaccine on 10/29/21.  Patient is not of approved age to receive.  Error was found 11/1/2021.  I contacted legal guardian (grandmother),  11/1/2021 at 0220pm.  She was appreciative of the contact and informed me that he had no side effects at all from the vaccine.  I informed her that the second dose should be of the covid-Pfizer vaccine in 28 days.  Asked her to notify me if any adverse events where noticed at any time.
Since July 4th I have felt as though I can't breathe, exercise is difficult and I haven't been sleeping because it's harder to breathe when I lay down. I have chest tightness and pain.
The pt developed a local reaction; red, warm to touch and swelling 3" X 3" in diameter.
pt recv vax 20NOV98 in the Am by afternoon site was red & swollen by that evening;pt had hives all over body, face was swollen;pt given rx strength DPh by MD;
I had the usual fatigue, chills, fever, body aches. But I also had severe rigor and my left arm, wrist, hand, and fingers were contracted up against my body. I can move my arm today but it's very sore and my fine motor is weak.
This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (felt like my arm hurt and arm soreness), NERVOUSNESS (little edgy and nervous last night), VACCINATION SITE RASH (injection site rash and redness and itching), VACCINATION SITE ERYTHEMA (injection site rash and redness and itching) and VACCINATION SITE PRURITUS (injection site rash and redness and itching) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 036A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was Provided by the reporter.  Concomitant products included ATORVASTATIN, LOSARTAN POTASSIUM, VITAMINS NOS (MTV), CALCIUM, CALCIUM CARBONATE, COLECALCIFEROL (VITAMIN D 2000), ASCORBIC ACID, ROSA CANINA FRUIT (VITAMIN C & ROSEHIP), AZELASTINE HYDROCHLORIDE (ASTEPRO) and OMEPRAZOLE (PRILOSEC [OMEPRAZOLE]) for an unknown indication.    On 06-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Mar-2021, the patient experienced PAIN IN EXTREMITY (felt like my arm hurt and arm soreness). On 21-Mar-2021, the patient experienced NERVOUSNESS (little edgy and nervous last night), VACCINATION SITE RASH (injection site rash and redness and itching), VACCINATION SITE ERYTHEMA (injection site rash and redness and itching) and VACCINATION SITE PRURITUS (injection site rash and redness and itching). On an unknown date, the patient experienced MYALGIA (achiness) and FATIGUE (fatigue, described as feeling weak). At the time of the report, PAIN IN EXTREMITY (felt like my arm hurt and arm soreness), NERVOUSNESS (little edgy and nervous last night), VACCINATION SITE RASH (injection site rash and redness and itching), VACCINATION SITE ERYTHEMA (injection site rash and redness and itching), VACCINATION SITE PRURITUS (injection site rash and redness and itching), MYALGIA (achiness) and FATIGUE (fatigue, described as feeling weak) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment medications were reported.  Follow-up received on 04-JUN-2021 date included no new information.   Most recent FOLLOW-UP information incorporated above includes: On 02-May-2021: Follow up received on 02-may-2021: Second dose vaccine details and events updated(created separate case for dose two) On 04-Jun-2021: Follow up received: 4 Jun 2021 No significant information updated
Systemic: Shakiness-Medium, Systemic: Tinnitus-Mild, Systemic: Visual Changes/Disturbances-Mild, Additional Details: Patient report vision distortion and ringing in the ears.  Symptoms subsided with 15 minute waiting period.  Patient also reported feeling shaky, symptoms subsided within 30 minutes of injection
Admitted on 1/22 with acute renal failure, dehydration, eleveated lactic acid, severe sepsis from COVID-19.  Symprtoms started several days before presentation and COVID-19 + on admission. Given 3 liters IVF. Creatinine greater than 4 with baseline of 0.8-0.9. Taking losartan with HCTZ at home.EKG shows sinus rhythm with no eveidence of acute ischemia or infarction. Hhg oxygen requirments with D-dimer done.  Seen hours later and looked improved clinically compared to when in the ER.  Patient was found by phlembotomy blue and unresponsive. Code blue without response.
A few minutes after receiving vaccines, approx 8:10pm, the pt fainted and fell in the exam room. The fall was witnessed by the pt's aunt. Per pt's aunt, the pt "got up from the table, fainted, fell and hit his head on the floor." When the nurse arrived to the room, the pt was laying on the floor with the aunt rubbing his head. Pt opened his eyes. The doctor was immediately called to the room and vital signs were taken. Pt denied pain and dizziness. Pt slowly got up from the floor and was able to sit on the table. Pt denied nausea, dizziness, and pain. The doctor assessed the pt and completed a neuro exam. The doctor advised the aunt to take the pt to the ER if pt c/o h/a, n/v, blurry vision. Pt stayed in waiting area for observation before leaving. Upon leaving, pt states he is feeling better. He continues to deny pain, dizziness, and nausea.
Starting that afternoon I was sore all over and very tired, foggy and nauseous for 2 days.    Those symptoms continued for 2 weeks except the nausea.   About 3 days in I lost taste and smell for 1 day.  The loss of taste came and went for maybe 1 month.   Sometimes now, I still have a loss of taste with certain foods and others do not taste like they used to taste.
Patient states that he felt super sick and lightheaded "(could not complete a thought)" for a couple hours after the shot. He also felt very spaced out and "drugged"  He called me today to report that he still felt mild lightheadedness and spaciness even after 10 days.
This spontaneous report was received from a healthcare worker and refers to multiple unspecified patients of unknown age and gender. The patients' pertinent medical history, drug reactions or allergies and concomitant therapies were not reported. On unknown dates after 18-NOV-2015, the patients were vaccinated with improperly stored doses of VARIVAX (Merck) (exact dose and route were not reported, lot # K006135 with expiration date: 29-APR-2016, lot # K011083 with expiration date: 08-AUG-2016). The administered doses experienced a temperature excursion of 71 degrees Fahrenheit for 30 minutes. There was no previous temperature excursion. No adverse effects were reported. Additional information has been requested.
Patient developed shingles from the vaccine and said her vision was off. She received treatment from her doctor.
pt states she had a sore left arm.  She went to her PCP next day on 3/25/2021 for already scheduled appt to have labs.  The INR test read 3.9 and is normally 2.5 or 2.6.  She was told this was extremely high.  She had to go back on 4/5/2021 and have a repeated INR test and it was back down to 2.6.  She feels like taking the Vax made this test result to be higher than normal since there had been no other changes in taking her meds at that time.
Information has been received from a medical assistant concerning a female with neck strain and pharyngitis who in the past was vaccinated with MMR II. Concomitant therapy included CELEXA, KLONOPIN, rizatriptan benzoate and REGLAN. The patient had low titers for mumps. The mumps IgG was 0.33 and the mumps IgM was 0.36. The patient did not seek any medical attention. Additional information has been requested.
Received 2nd dose Shangrix on 11/29. Muscle and body soreness for 2-3 days. Developed ringing in ears on 12/1. Slightly reduced vision on 12/1.
Patient came to the ED with angioedema of the lips/face that started about 54 hrs after vaccine administration. no other clear triggers were obvious other than the recent vaccine administration.
Pt reported on 1/25/12 am swelling along (L) arm around deltoid area later in pm same day noted swelling increased & included from shoulder to elbow & intense itching present. Observed in clinic on 1-26-12 & sl redness to vaccine site & swelling same as reported.
This medically confirmed spontaneous report (initial receipt 24-Sep-2013) concerns a 55-year-old female patient with no allergies. Concomitant medication included levothyroxine. On 23-Sep-2013, the patient was administered intramuscular AFLURIA (batch number R54307) at a dose of 0.5ml. On 23-Sep-2013, within 8-12 hours post-vaccination, the patient developed severe redness of the eyes, throat and uvula along with discomfort swallowing. There was no evidence of swelling. That evening, on the 23-Sep-2013, the patient attended an emergency room and was treated with an unspecified injectable steroid and an unspecified non-narcotic analgesic. As of the 24-Sep-2013, the redness in the eyes was greatly diminished, some of the redness in the throat had diminished and the patient still had some difficulty swallowing. Outcome was reported as recovering.
Unknown! Sent an email to Dr, the father of child. No response yet. No working phone number.
Information has been received from a physician concerning a teenage girl believed to be 17 year old who on an unknown date was vaccinated with GARDASIL vaccine (yeast). The physician reported that a patient developed severe headaches after received GARDASIL vaccine (yeast). The patient is currently seeing a neurologist (name unspecified) and taking NEURONTIN for the headaches. There was no product quality complaint. Additional information has been requested.
rash all over her stomach; a little pain at injection site; This is a spontaneous report from a contactable nurse (patient).  A 64-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 13Jan2021 at 15:00 at single dose for COVID-19 immunization.  The patient medical history and concomitant medications were not reported. On 13Jan2021, the patient experienced rash all over her stomach (7 hours after vaccination) and a little pain at injection site. The patient outcome of the events was unknown.   The information on the batch number has been requested.
This initial non-serious spontaneous case, was received on 01-Nov-2017, from a physician, concerning adult male patient of unspecified age. This refers to the 78th out of 84 patients. On an unspecified date in Oct-2017 (between 25-Oct-17 to 27-Oct-17), the patient was administered with AFLURIA Thiomersal (batch number: 14649211A, dose, route of administration, anatomical location and expiry date: not reported). It was reported that, the vaccine was stored in cooler with ice packs for 6 days and had reached unknown temperature during transport (explicitly considered as incorrect product storage) instead of storing at 36-degree F and 46-degree F (2-degree C and 8-degree C). And the same was administered to the patient (explicitly considered as drug administration error). The reporter stated that the temperature was not monitored on 24-Oct-2017 (could have been between 2-8C, but not certain) and there were no reports of adverse effect after vaccination (no adverse effect). The vaccine had been discarded. Follow up received on 09-Nov-2017 from a physician: Added event (no adverse effect) and reporters comment. Amended narrative accordingly.
"red all over"; numbness, burning and tingling for the last 3 months; Burning in hands; numbness, burning and tingling for the last 3 months; shoulder pain for 3 months; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA ("red all over"), the first episode of PARAESTHESIA (numbness, burning and tingling for the last 3 months), BURNING SENSATION (Burning in hands), the second episode of PARAESTHESIA (numbness, burning and tingling for the last 3 months) and ARTHRALGIA (shoulder pain for 3 months) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 27-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 02-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to at an unspecified dose. On an unknown date, the patient experienced ERYTHEMA ("red all over"), the first episode of PARAESTHESIA (numbness, burning and tingling for the last 3 months), BURNING SENSATION (Burning in hands), the second episode of PARAESTHESIA (numbness, burning and tingling for the last 3 months) and ARTHRALGIA (shoulder pain for 3 months). The patient was treated with GABAPENTIN for Adverse event, at a dose of 1 dosage form. At the time of the report, ERYTHEMA ("red all over"), BURNING SENSATION (Burning in hands), the last episode of PARAESTHESIA (numbness, burning and tingling for the last 3 months) and ARTHRALGIA (shoulder pain for 3 months) outcome was unknown.            Treatment:  Muscle relaxant are used. Concomitant medication was not provided.
had a sore arm; This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm was recovered/resolved.   It was unknown if the reporter considered the pain in arm to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was selected as an adult as per vaccine indication. The patient had first Shingrix shot and had a sore arm for about a week.  The patient asked if the second shot had worse effects.
Patient with MS on Tysabri received Moderna COVID-19 vaccine full dose on 01/22/2021 and 02/25/2021; then received Moderna COVID-19 vaccine booster dose on 10/28/2021 and 02/23/2022, instead of a third full dose of primary series.
fast heartbeat; weakness; difficulty breathing; dizziness; Initial information received on 05-Oct-2022 and live follow-up received on same day (processed together) regarding an unsolicited valid serious case received from a consumer/non-hcp.  This case involves an unknown age female patient who had fast heartbeat, weakness, difficulty breathing and dizziness after receiving vaccine INFLUENZA VACCINE.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included COVID-19 VACCINE (COVID-19 VACCINE) for Immunisation.  On 12-Sep-2021, the patient received an unknown dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (strength, formulation was unknown, lot 312832 and expiry date: 11-May-2022) via unknown route in unknown administration site for Immunization.  On an unknown date the patient developed a serious event of fast heartbeat (heart rate increased), weakness (asthenia), difficulty breathing (dyspnoea) and dizziness (latency: unknown) following the administration of INFLUENZA VACCINE. Patient had a bad experience after receiving the Seqirus flu shot last year (2021), and still have not recovered. Patient ended up on a rehabilitation unit for 43 days, and was still weak from it. Patient denied facial swelling. patient went to hospital and was admitted for ten days. Patient used it for the first time.  Action taken: not applicable.  It was not reported if the patient received a corrective treatment for the events.   Outcome: Not Recovered for all events.  Seriousness criteria: Hospitalized for all events.; Sender's Comments: Sanofi company comment dated 10-Oct-2022: This case involves an unknown age female patient who had fast heartbeat, weakness, difficulty breathing and dizziness after receiving vaccine INFLUENZA VACCINE.  The time to onset was not reported with the vaccine. Further information regarding medical history, concurrent condition during vaccination, previous vaccination, concomitant medication and tolerance, allergic history, laboratory investigations excluding alternative etiologies for the reported event are needed to fully assess this case. Based upon the few reported information, the role of the suspect vaccine cannot be assessed.
This spontaneous report as received from a consumer refers to consumer's friend an 65 year old patient on an unknown gender. On an unknown date the patient was vaccinated with ZOSTAVAX, injection (strength, dose, route not provided) got very sick and had to go home from work. The outcome of event was unknown. This report is one of 2 reports from the same source. Additional information has been requested.
Front desk received white cards from patients and passed on the news that there were 2 second dose Moderna patients coming in. they were placed on our Moderna side and the vaccine given. The MA noticed that the cards were Pfizer 1st dose after the vaccine was given.    The patient was observed for half and hr. Side effects and information was given to the patient about the Moderna vaccine. Patient was advised to seek medical attention if any adverse symptoms arise, such as chest pain, shortness of breath, or etc.
Skin rash, urticaria pruritus, swelling. Prednisone PO, hydrocortisone BID.
sore arm; swelling; This case was reported by a other health professional via sales rep and described the occurrence of pain in arm in a adult patient who received Men B NVS (Bexsero) for prophylaxis.   On an unknown date, the patient received the 1st dose of Bexsero. On an unknown date, unknown after receiving Bexsero, the patient experienced pain in arm and swelling. On an unknown date, the outcome of the pain in arm and swelling were unknown.   It was unknown if the reporter considered the pain in arm and swelling to be related to Bexsero.  Additional details were provided as follows: The age at vaccination was not reported. The health care professional stated that she had experienced adverse events sore arm, swelling with Bexsero.  The health care professional also stated that it seemed to be higher incidence after 1st dose than 2nd dose. This case has been linked with case US2019GSK101167, reported by the same reporter.
This spontaneous report as received from a nurse refers to an unknown patients of unknown age and gender. No pertinent medical history, drug reactions/allergies and concomitant medications were reported. On an unknown date the patients were vaccinated with improperly stored doses of PNEUMOVAX 23 (lot# L021637 and expiry date 05-NOV-2016) and (lot#L019836 and expiration date 24-MAR-2017) subcutaneously (also reported as depends on the vaccine). The vaccine was exposed to temperature excursion of 1.4C for 21 minutes. No previous temperature excursion was reported. No adverse events were reported. No product quality complaint was filed. This is one of several reports received from the same reporter. Additional information has been requested.
This spontaneous report as received from a Registered Nurse refers to a patient of unknown age and gender. No medical history and concurrent conditions were reported. On 23-FEB-2015 the patient was vaccinated with VARIVAX (Merck) with lot # K007781 (expiration date, dose, route, frequency and indication were not reported) that experienced a temperature excursion, which was later supported as well. There was no concomitant medication reported. At the time of the report, the patient's status was unknown. This is one of several reports received from the same reporter. Additional information has been requested.
pt received 1st dose of moderna, 3 months after getting J&J, no actual adverse events, just reporting that it was given to patient, and per CDC guidelines we should not administer a different covid vaccine to a patient who has already received a different one
Medium sized red, warm, sore, itchy rash at injection site appearing 12 days after the shot.
earliest appointment for second dose is 52 days after first dose; A spontaneous report was received from a consumer, who was also a male patient of unknown age, who received Moderna's COVID-19 vaccine (mRNA-1273) and the earliest appointment for second dose is 52 days after first dose (inappropriate schedule of product administration).  The patient's medical history was not provided. Concomitant product use was not reported.   On 27 JAN 2021  the patient received their first of two planned doses of mRNA-1273 (Lot number: unknown) for prophylaxis of COVID-19 infection.   The patient reported that the earliest appointment for second dose is on 20 Mar 2021, 52 days after the first dose.  Action taken with mRNA-1273 in response to the events was not applicable.  The event of earliest appointment for second dose is 52 days after first dose was considered resolved.; Reporter's Comments: This report refers to a case of inappropriate schedule of vaccine administered for mRNA-1273 (lot #unknown) with no associated AEs reported
fatigue; muscle aches; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6203), via an unspecified route of administration in the left arm on 18Mar2021 at 10:00 (at the age of 44-years-old), as a single dose for COVID-19 immunisation. Medical history included hypertension. Allergies to medications, food, or other products reported to avocado. Concomitant medications included amlodipine (MANUFACTURER UNKNOWN), multivitamins (MANUFACTURER UNKNOWN), both from unknown dates for unspecified indications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: unknown), via an unspecified route of administration on 25Feb2021 at 10:00 (at the age of 44-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 19Mar2021 at 15:00, the patient experienced fatigue and muscle aches. The patient received treatment for the events fatigue and muscle aches which included ibuprofen . The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The outcome of the fatigue and muscle aches was recovered on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
05/23/2022 I was at work and had just eaten lunch. I turned my head and got incredibly dizzy. I then became nauseous and it would cause me to throw up. I then got taken to the ER and had a CT Scan of the Head and Neck, an MRI, an Echo and all the results that came back were normal. I was given some medication to help with the Vertigo, Meclizine, and also a medication for the nausea. I did stop throwing up however I was still having dizziness occur. I couldn't stand up due to the dizziness and I was on fall alert until I was discharged. I did stay in the hospital until the 05/25/2022. My symptoms had subsided since leaving the hospital.
Patient started to shake after Covid vaccination. Her vital sign was checked. She was referred to EMS. EMS checked BP/BS.
Myocardial infarction type 2. ED visit to hospital admission. This visit was within 6 weeks of receiving the COVID vaccine.
rash/redness around injection site. informed pt to take Tylenol or ibuprofen and to call Dr ASAP if any symptoms of allergic reaction, or if the rash increased in size.